Andrew Sabers

Critical Care Pharmacist @uihealthcare | PGY1/PGY2 Critical Care Pharmacy Residency @NebraskaMed | PharmD 💊 @UIpharmacy | Interests: ECMO, Shock, Anticoag

[SCCM Clinical Pharmacy and Pharmacology Section @SCCM_CPP]

Please join us for our monthly @SCCM Spotlight on Pharmacy CPP Journal Club 4/19 at 1pm Central/2pm Eastern! Presenters and articles are listed below. Register here: https://t.co/Hk1MTag5GU
#PharmICU #SCCMJC

[Andrew Sabers @asaberspharm]

For all those participating in phase 2, I highly recommend checking out Nebraska Med! The program is full of exceptional preceptors and @pfullerusa is an incredible RPD!!! If that doesn’t convince you the buffalo wraps will!

[Andrew Sabers @asaberspharm]

@transplantID Also AMS or a fall are not urinary symptoms❗️

[Andrew Sabers @asaberspharm]

‼️‼️‼️

[IMCrit @IM_Crit_]

ICU Pharmacology Secrets - Etoh withdrawal:

I heard today from a resident (when I asked if a pt had received phenobarbital): "my attending prefers Precedex (dexmedetomidine) for etoh withdrawal"

Friendly reminder: Dexme is not etiologic treatment for etoh withdrawal. The real

[Andrew Sabers @asaberspharm]

@PharmDFarmD Not just non-inferior, but also a significant reduction in AKI!

[Intensive Care Medicine @yourICM]

Pharmacy professionals in #ICU??
💊to ⬆️ outcomes & #ptsafety
💊optimize medication & dosing in MOF & TDM
💊reconciliation at transitions of care
💊support nurses
💊drug delivery & stock supply
💊research
💊education & EB pharmacotherapy
💊cost–benefit
🔓 https://t.co/74dUyCwGoA

[Andrew Sabers @asaberspharm]

@saraharduser Congrats Sarah! So happy for you!!!

[Andrew Sabers @asaberspharm]

@ruxyID We did when I was at Nebraska Med. https://t.co/HkSbIQ4P2d

[Andrew Sabers @asaberspharm]

@cardionate Combining safety and efficacy endpoints into a composite for a non-inferiority trial, have we no limits? 😂

[Brad Spellberg @BradSpellberg]

@ABsteward @DrToddLee I hate to be "that guy". But, heck, I am that guy.
Neither cefepime NOR pip tazo should be empiric Tx for community infections going to ICU. Pseudomonal agents should be reserved for HAIs. Overuse of these Abx is 1 of the great failings of national stewardship efforts/guidelines.

[Andrew Sabers @asaberspharm]

@PCC_PharmD 4F-PCC arm is definitely more ill at baseline compared to andexa arm. Larger ICH, poorer mental status, higher transfusion requirements, etc. Interesting study but, this controversy is going to be hard to put to bed without an RCT or a well done propensity matched analysis

[Andrew Sabers @asaberspharm]

@drmvalente @StrokeAHA_ASA Not to mention a OR of 1.86 for thromboembolism, highly questionable efficacy with potential harm… and it has no mechanism to reverse DOAC associated bleeding

[Zaven Sargsyan @sargsyanz]

What’s a stronger regimen of furosemide, 40 daily or 20 bid?

I ask this question often on rounds. The answer: it depends.

Understanding what it depends ON is really helpful for dosing decisions.

Let’s explore. #tweetorial 1/

[Andrew Sabers @asaberspharm]

@cardionate Congratulations!!!

[SCCM Clinical Pharmacy and Pharmacology Section @SCCM_CPP]

Does lidocaine vs. amiodarone in patients with in IHCA caused by VT/VF impact patient outcomes?

Check out our Education Committee's infographic for a summary of last month's #SCCMJC! #PharmICU @KaitlinLandolf @journal_CHEST

🔗 Full article: https://t.co/FH3HQFRHqI

[Shawna Sunagawa @shawna_san]

literally the BEST team 🤩

[Andrew Sabers @asaberspharm]

@_emilylynn_ Congrats!!!

[Andrew Sabers @asaberspharm]

Looking for ideas for a pro-con debate, anyone have a good idea? #TwitteRx #pharmicu

[Andrew Sabers @asaberspharm]

@amandav_pharmd Good luck!!!

[Andrew Sabers @asaberspharm]

@BrannanMd Thank you Dr. Brannan!